JP2008535853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535853A5 JP2008535853A5 JP2008505600A JP2008505600A JP2008535853A5 JP 2008535853 A5 JP2008535853 A5 JP 2008535853A5 JP 2008505600 A JP2008505600 A JP 2008505600A JP 2008505600 A JP2008505600 A JP 2008505600A JP 2008535853 A5 JP2008535853 A5 JP 2008535853A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- prlr
- antibody
- level
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 238000000034 method Methods 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 25
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 23
- 102100029000 Prolactin receptor Human genes 0.000 claims 23
- -1 LOC390243 Proteins 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 19
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 18
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 18
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims 14
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 14
- 102100022509 Cadherin-23 Human genes 0.000 claims 13
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 claims 13
- 102100034613 Annexin A2 Human genes 0.000 claims 12
- 102100021253 Antileukoproteinase Human genes 0.000 claims 12
- 102100031403 Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Human genes 0.000 claims 12
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 12
- 102100031161 Collagen alpha-1(XIX) chain Human genes 0.000 claims 12
- 102100022640 Collagen alpha-1(XV) chain Human genes 0.000 claims 12
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 12
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims 12
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 12
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 12
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 12
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 12
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 12
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 12
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 claims 12
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 claims 12
- 101001130526 Homo sapiens Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Proteins 0.000 claims 12
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 12
- 101000940120 Homo sapiens Collagen alpha-1(XIX) chain Proteins 0.000 claims 12
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 claims 12
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 claims 12
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims 12
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims 12
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 12
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 12
- 101001035232 Homo sapiens Integrin alpha-9 Proteins 0.000 claims 12
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 claims 12
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 12
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 12
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 12
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 claims 12
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 12
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 12
- 101001077426 Homo sapiens Potassium voltage-gated channel subfamily H member 5 Proteins 0.000 claims 12
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 12
- 101000781955 Homo sapiens Proto-oncogene Wnt-1 Proteins 0.000 claims 12
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 claims 12
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims 12
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 12
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims 12
- 101000846336 Homo sapiens Ribitol-5-phosphate transferase FKTN Proteins 0.000 claims 12
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 12
- 101000879840 Homo sapiens Serglycin Proteins 0.000 claims 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 12
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 12
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 claims 12
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 12
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 12
- 102100039903 Integrin alpha-9 Human genes 0.000 claims 12
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims 12
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 12
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 12
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 12
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims 12
- 108010072582 Matrilin Proteins Proteins 0.000 claims 12
- 102100033669 Matrilin-2 Human genes 0.000 claims 12
- 102000001759 Notch1 Receptor Human genes 0.000 claims 12
- 108010029755 Notch1 Receptor Proteins 0.000 claims 12
- 102100030368 Phospholipid phosphatase-related protein type 4 Human genes 0.000 claims 12
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 12
- 102100025071 Potassium voltage-gated channel subfamily H member 5 Human genes 0.000 claims 12
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 12
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 12
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims 12
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 claims 12
- 102100029197 SLAM family member 6 Human genes 0.000 claims 12
- 108091006626 SLC12A7 Proteins 0.000 claims 12
- 102000012980 SLC1A2 Human genes 0.000 claims 12
- 108091006529 SLC28A2 Proteins 0.000 claims 12
- 108091006660 SLC9A9 Proteins 0.000 claims 12
- 102100029967 Sodium/hydrogen exchanger 9 Human genes 0.000 claims 12
- 102100021541 Sodium/nucleoside cotransporter 2 Human genes 0.000 claims 12
- 102100034252 Solute carrier family 12 member 7 Human genes 0.000 claims 12
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 claims 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 12
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 12
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims 12
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 12
- 102000052547 Wnt-1 Human genes 0.000 claims 12
- 102000052549 Wnt-3 Human genes 0.000 claims 12
- 102000044880 Wnt3A Human genes 0.000 claims 12
- 108700013515 Wnt3A Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 101150068520 wnt3a gene Proteins 0.000 claims 12
- 102100032936 Carboxypeptidase M Human genes 0.000 claims 11
- 108090000007 Carboxypeptidase M Proteins 0.000 claims 11
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 11
- 101001137975 Homo sapiens Leucyl-cystinyl aminopeptidase Proteins 0.000 claims 11
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 claims 11
- 101150091468 IGSF8 gene Proteins 0.000 claims 11
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 claims 11
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 11
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims 11
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 claims 11
- 102100035873 Tetraspanin-2 Human genes 0.000 claims 11
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 10
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 10
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 10
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims 10
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 10
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 10
- 102100022766 R-spondin-3 Human genes 0.000 claims 10
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 10
- 101710151638 Tetraspanin-2 Proteins 0.000 claims 10
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims 9
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 claims 9
- 101000841325 Homo sapiens Urotensin-2 Proteins 0.000 claims 9
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims 9
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims 9
- 108010029751 Notch2 Receptor Proteins 0.000 claims 9
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 claims 9
- 102100029097 Urotensin-2 Human genes 0.000 claims 9
- 102100036411 Dermatopontin Human genes 0.000 claims 8
- 101000929047 Homo sapiens Dermatopontin Proteins 0.000 claims 8
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 8
- 102100033467 L-selectin Human genes 0.000 claims 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 8
- 206010005003 Bladder cancer Diseases 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 7
- 206010038389 Renal cancer Diseases 0.000 claims 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 7
- 201000010881 cervical cancer Diseases 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 7
- 206010017758 gastric cancer Diseases 0.000 claims 7
- 201000010982 kidney cancer Diseases 0.000 claims 7
- 201000007270 liver cancer Diseases 0.000 claims 7
- 208000014018 liver neoplasm Diseases 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 201000000849 skin cancer Diseases 0.000 claims 7
- 201000011549 stomach cancer Diseases 0.000 claims 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims 7
- 206010046766 uterine cancer Diseases 0.000 claims 7
- 102100031510 Fibrillin-2 Human genes 0.000 claims 6
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 claims 6
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims 5
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims 5
- 101000955355 Homo sapiens Xylosyltransferase 1 Proteins 0.000 claims 5
- 108091006263 SLC4A8 Proteins 0.000 claims 5
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 claims 5
- 102100038983 Xylosyltransferase 1 Human genes 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 4
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims 4
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 4
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 4
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims 4
- 239000013610 patient sample Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims 3
- 230000001093 anti-cancer Effects 0.000 claims 3
- 108010079292 betaglycan Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000009739 binding Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101150015935 ATP2 gene Proteins 0.000 claims 1
- 101000658739 Homo sapiens Tetraspanin-2 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 101150026213 atpB gene Proteins 0.000 claims 1
- 210000003443 bladder cell Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66986105P | 2005-04-07 | 2005-04-07 | |
| PCT/US2006/013153 WO2006110581A2 (en) | 2005-04-07 | 2006-04-07 | Cancer-related genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535853A JP2008535853A (ja) | 2008-09-04 |
| JP2008535853A5 true JP2008535853A5 (enExample) | 2009-02-26 |
Family
ID=36809257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505600A Pending JP2008535853A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子 |
| JP2008505603A Pending JP2008535494A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子（ｐｒｌｒ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505603A Pending JP2008535494A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子（ｐｒｌｒ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090220495A1 (enExample) |
| EP (3) | EP1871911A2 (enExample) |
| JP (2) | JP2008535853A (enExample) |
| AU (1) | AU2006235258A1 (enExample) |
| CA (1) | CA2604844A1 (enExample) |
| WO (2) | WO2006110581A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| KR20090003178A (ko) | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| JP2009536834A (ja) | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| US20100021424A1 (en) * | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| US20100240035A1 (en) * | 2007-06-01 | 2010-09-23 | The Regents Of The University Of California | Multigene prognostic assay for lung cancer |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| EP2227556B1 (en) * | 2007-11-19 | 2014-08-27 | Celera Corporation | Lung cancer markers and uses thereof |
| CA2718854A1 (en) * | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| BRPI0912683A2 (pt) | 2008-05-15 | 2016-01-26 | Transmolecular Inc | tratamento de tumores metastáticos |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| EP3115063A3 (en) * | 2008-12-03 | 2017-04-19 | The John Hopkins University | Galectin-3 and annexin-a2 as immunological target |
| WO2010127322A1 (en) | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013044164A1 (en) * | 2011-09-21 | 2013-03-28 | The Regents Of The University Of California | Methods to treat and/or prevent relapse in notch1-driven malignancies |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| EP2812350B1 (en) * | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013166153A2 (en) * | 2012-05-01 | 2013-11-07 | Brentnall Teri | Methods and compositions for cancer diagnosis |
| KR102082099B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140179560A1 (en) | 2012-12-10 | 2014-06-26 | Fred Hutchinson Cancer Research Center | Drug discovery methods and platforms |
| TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與ｗｎｔ抑制劑相關之標記 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| EP3091999B2 (en) | 2014-01-09 | 2025-05-07 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| JP2020529870A (ja) | 2017-08-10 | 2020-10-15 | ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル | がんを層別化し、処置するための材料及び方法 |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
| KR101890392B1 (ko) * | 2018-05-28 | 2018-08-21 | 의료법인 성광의료재단 | Ｗｎｔ３ａ를 포함하는 난소암의 진단을 위한 마커 및 조성물 |
| KR20200115883A (ko) * | 2019-03-28 | 2020-10-08 | 황인후 | 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| US20220326243A1 (en) * | 2019-05-21 | 2022-10-13 | Acurasysbio Co., Ltd. | Composition for cancer diagnosis |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| EP4081253A4 (en) * | 2019-12-25 | 2023-09-06 | Shanghai XBH Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN114487418A (zh) | 2022-02-17 | 2022-05-13 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | TGFb RIII蛋白作为胃癌血清生物标志物的应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| CA2049028A1 (en) | 1989-03-07 | 1990-09-08 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| RU2142467C1 (ru) | 1990-07-27 | 1999-12-10 | Чирон Диагностикс Корпорейшн | Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP3337214B2 (ja) | 1990-12-20 | 2002-10-21 | アーチ・ディベロップメント・コーポレーション | 電離線による遺伝子発現の調節 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| EP1295952A3 (en) | 1996-01-23 | 2003-07-09 | The Board of Trustees of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| WO2002050098A2 (en) * | 2000-12-18 | 2002-06-27 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the prlr gene |
| US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP1466016A2 (en) * | 2002-01-09 | 2004-10-13 | Riken Institute Of Physical And Chemical Research | Cancer profiles |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP2233572A3 (en) * | 2002-06-06 | 2011-01-12 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human colon cancers |
| WO2004016317A1 (en) * | 2002-08-14 | 2004-02-26 | Erasmus University Medical Center Rotterdam | Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| PL1651162T3 (pl) | 2003-05-20 | 2016-04-29 | Immunogen Inc | Maitansynoidy w leczeniu nowotworów |
| WO2004105573A2 (en) * | 2003-05-21 | 2004-12-09 | The Wistar Institute Of Anatomy And Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| JP2006526998A (ja) * | 2003-06-12 | 2006-11-30 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 胃癌および転移性胃癌診断キット |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| JP2005073548A (ja) * | 2003-08-29 | 2005-03-24 | National Cancer Center-Japan | 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用 |
| JP2007506425A (ja) * | 2003-09-24 | 2007-03-22 | オンコセラピー・サイエンス株式会社 | 肝細胞癌を診断する方法 |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP1805519B1 (en) * | 2004-09-21 | 2013-11-06 | Rhode Island Hospital | Wnt proteins and detection and treatment of cancer |
-
2006
- 2006-04-07 JP JP2008505600A patent/JP2008535853A/ja active Pending
- 2006-04-07 JP JP2008505603A patent/JP2008535494A/ja active Pending
- 2006-04-07 CA CA002604844A patent/CA2604844A1/en not_active Abandoned
- 2006-04-07 EP EP06749567A patent/EP1871911A2/en not_active Ceased
- 2006-04-07 EP EP09001181A patent/EP2083088A3/en not_active Withdrawn
- 2006-04-07 WO PCT/US2006/013153 patent/WO2006110581A2/en not_active Ceased
- 2006-04-07 US US11/910,837 patent/US20090220495A1/en not_active Abandoned
- 2006-04-07 AU AU2006235258A patent/AU2006235258A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013160 patent/WO2006110585A2/en not_active Ceased
- 2006-04-07 EP EP06749562A patent/EP1910557A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535853A5 (enExample) | ||
| US11970745B2 (en) | Method for assessing a prognosis and predicting a response of patients with malignant diseases to immunotherapy | |
| JP4568716B2 (ja) | 遺伝子発現を測定するためのイントロンｒｎａの使用 | |
| US8153378B2 (en) | Gene expression markers for colorectal cancer prognosis | |
| JP6404304B2 (ja) | メラノーマ癌の予後予測 | |
| US20120028264A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| US20160208329A1 (en) | Systems, devices and methods for anti-tl1a therapy | |
| CN102753704A (zh) | I型干扰素诊断 | |
| JP2006518602A5 (enExample) | ||
| WO2011109637A1 (en) | Methods for classifying and treating breast cancers | |
| JP2021502069A (ja) | がんを検出するための非コードｒｎａ | |
| JP7646577B2 (ja) | 胃癌を診断するための高メチル化遺伝子の検出 | |
| CN107488737A (zh) | 一种检测外周血tcr可变区编码基因的液体活检试剂盒及其应用 | |
| US11685955B2 (en) | Method for predicting response of patients with malignant diseases to immunotherapy | |
| CN110229899A (zh) | 用于结直肠癌早期诊断或预后预测的血浆标记物组合 | |
| AU2015227398B2 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| US20240336975A1 (en) | Biomarkers Predicting Response of Breast Cancer to Immunotherapy | |
| JP7191984B2 (ja) | 分析方法及びキット | |
| CN115666590A (zh) | 口腔鳞癌相关生物标志物及诊断和治疗方法 | |
| AU2017270496B9 (en) | Determination of genetic predisposition to aggressive prostate cancer | |
| US20250179579A1 (en) | Method of detecting urothelial or bladder cancer in a liquid sample | |
| WO2007086351A1 (ja) | ５－フルオロウラシル系抗癌剤に対する感受性を予測する方法 | |
| JP2012000081A (ja) | Ｓｎｐによる肥満化のリスクの予測 | |
| WO2015037681A1 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット |